A report from the World Heart Federation provides an overview of transthyretin amyloid cardiomyopathy (ATTR-CM), including tools for diagnosis and patient management, highlighting the importance of ...

Near-complete in vitro TTR stabilization was observed as early as day 28 and through completion of a 30-month study of patients with ATTR-CM. The Food and Drug Administration (FDA) has approved ...

Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with ...

A PDUFA target date of November 29, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for acoramidis for the treatment of ...

"Our study clearly demonstrates that the QoL among patients with ATTR is significantly reduced…QoL is of course important in every patient but I think it is even more important in these elderly ...

Please provide your email address to receive an email when new articles are posted on . Cardiac MRI data suggest acoramidis could improve outcomes for people with symptomatic transthyretin amyloid ...

CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ...

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday that the European Commission or EC has granted approval for AMVUTTRA (vutrisiran) for the treatment of wild-type or hereditary ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Acoramidis reduced risk for all-cause mortality and ...

One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple ...

The evaluation committee considered evidence submitted by Alnylam Pharmaceuticals, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the ...